Evaluating outcomes after catheter ablation for atrial fibrillation
PROSPective Evaluation of Outcome After CatheTer Ablation in Atrial Fibrillation : LONGITUDINAL STUDY OF PATIENTS UNDERGOING RADIOFREQUENCY ABLATION OF ATRIAL FIBRILLATION.
This study is trying to find out what factors might cause atrial fibrillation to come back after treatment with catheter ablation in patients, while also looking at the risk of serious heart problems and bleeding.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 750 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Lille Academic / other |
| Locations | 1 site (Lille) |
| Trial ID | NCT05009797 on ClinicalTrials.gov |
What this trial studies
This study aims to identify predictors of atrial fibrillation recurrence within three years following catheter ablation in a cohort of 750 patients. It will analyze clinical variables and innovative biomarkers to understand the factors contributing to AF recurrence. Additionally, the study will assess the incidence of major adverse cardiovascular outcomes and major bleeding events in the same timeframe. By focusing on these outcomes, the research seeks to improve patient management and treatment strategies for atrial fibrillation.
Who should consider this trial
Good fit: Ideal candidates for this study are patients scheduled to undergo catheter ablation for atrial fibrillation who can provide informed consent.
Not a fit: Patients who are children, under guardianship, unable to give consent, or pregnant will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved strategies for preventing atrial fibrillation recurrence and enhancing patient outcomes.
How similar studies have performed: Other studies have explored similar approaches in understanding atrial fibrillation recurrence, but this specific study focuses on innovative biomarkers, making it a novel contribution.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient undergoing atrial fibrillation catheter ablation * Able to give their consent Exclusion Criteria: * Childs * Patient under guardianship * Patients unable to give their consent * Pregnancy
Where this trial is running
Lille
- Institut Coeur-Poumon, CHU — Lille, France (Recruiting)
Study contacts
- Principal investigator: Sandro Ninni, MD — University Hospital, Lille
- Study coordinator: Sandro Ninni, MD
- Email: sandro.ninni@chru-lille.fr
- Phone: 0320445962
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.